Bristol-Myers Squibb Company (ETR:BRM)
42.45
+0.14 (0.32%)
Jun 6, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.93
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
85.02B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.17B |
Fielmann Group AG | 2.33B |
Bristol-Myers Squibb Company News
- 2 days ago - BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped - Seeking Alpha
- 4 days ago - Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet - CNBC
- 4 days ago - Why BioNTech Stock Soared Today - The Motley Fool
- 4 days ago - Watch CNBC's full interview with Bristol Myers CEO Christopher Boerner - CNBC
- 4 days ago - Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer - CNBC
- 4 days ago - BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration - Investopedia
- 4 days ago - Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug - Benzinga
- 4 days ago - Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race - MarketWatch